Dual-form IL-33 blockade distinguishes tozorakimab mechanistically from IL-4/13 or IL-5–axis biologics. Phase 2a clinical signals included numerical FEV1 improvement, fewer exacerbations, reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results